For a physician practice considering bringing molecular testing in house, the first questions are usually practical. How much space will the lab require? What equipment is needed? Who will staff it? What does certification involve? How will the lab connect to the EHR?
Those questions matter because they determine whether the laboratory can be built correctly. They do not fully answer what it takes to operate the lab once testing begins.
A physician-owned molecular lab requires ongoing infrastructure around staffing, quality, compliance, testing workflows, technology, reporting, reimbursement, and day-to-day management. Decisions made during development shape how well those functions work together later.
For a physician owner or COO, the larger question is not only whether the lab can be built. It is who will own the operating infrastructure required to make it perform over time.
ON THIS PAGE
The molecular lab usually gets built in pieces
After launch, the practice owns the gaps
A successful build does not guarantee a successful lab
Reimbursement belongs in the operating model
A different physician-owned lab model exists
The practice owns the lab and the ordering behavior
Determining if a practice is ready for an in-house molecular lab
The molecular lab usually gets built in pieces
The familiar path to an in-house molecular lab is fragmented for a reasonable reason: each part of the project requires specialized expertise.
Leadership may need to coordinate:
- an equipment company for instrumentation;
- a consultant for laboratory development and certification;
- technology providers for LIS and EHR connectivity;
- laboratory personnel and staffing resources;
- compliance and quality requirements;
- billing and reimbursement support.
A practice can work with capable people in every one of those areas and still end up without anyone responsible for the laboratory as a whole.
Each provider is accountable for its own scope. Once those pieces have been assembled, the practice becomes the point where they meet.
That distinction may not matter much while the lab is still a project. It matters considerably once the lab is processing tests every day.
After launch, the practice owns the gaps
A molecular laboratory has operating responsibilities that do not end with implementation. Laboratory personnel need ongoing oversight, testing and sample-handling workflows have to remain consistent, and quality, compliance, technology, and reporting all continue as part of daily operations.
The financial side is just as continuous. Claims need to move correctly through the revenue cycle, payer requirements have to be addressed, denials need attention, and leadership needs visibility into reimbursement and collections alongside testing volume and laboratory performance.
When different companies own those functions independently, the practice is left coordinating the points between them.
That becomes especially difficult when a problem crosses functional boundaries. A technology issue can affect ordering and reporting. An ordering error can create downstream billing problems. A staffing shortage can reduce testing capacity and change the economics of the lab.
At that point, leadership is not simply overseeing a laboratory. It is deciding where problems belong, which provider is responsible, and how the pieces should work together.
That creates an operating role many practices did not intend to build for themselves.
A successful build does not guarantee a successful lab
A laboratory can reach opening day with the right equipment, qualified personnel, working technology, and the required approvals and still fall short of the expectations established during planning.
The reasons tend to appear after launch.
Implementation may stretch when dependencies between providers surface. Capacity may not translate into actual testing volume. Physicians may continue sending appropriate testing to reference laboratories out of habit. Staff may not follow the ordering workflow consistently. Billing performance may not match the assumptions used in the original financial model.
A pro forma can describe what a laboratory could produce. It cannot create the operating conditions required to produce it.
That is where laboratory development and laboratory management begin to separate. A consultant can be accountable for getting a laboratory built without remaining accountable for what happens to turnaround time, utilization, reimbursement, staffing, or financial performance a year later.
For practice leadership, the value of an in-house molecular lab depends much more on that second period than the first.
Reimbursement belongs in the operating model
Lab reimbursement is one of the easiest functions to treat as a downstream concern only after the numbers aren’t adding up.
The clinical side of the laboratory is visible early. The practice needs space, equipment, personnel, testing processes, and technology before the first test can be performed. Billing can appear to be something that follows naturally once those pieces are in place.
In practice, many of the decisions that determine reimbursement happen well before a claim is submitted.
A reliable financial model depends on several connected steps:
- the test is ordered correctly;
- documentation supports the service;
- coding and payer requirements are addressed;
- claims move through the revenue cycle;
- denials, patient billing, collections, and reporting are managed appropriately.
That work is specialized enough that it should influence the laboratory model from the beginning.
A molecular lab can be clinically capable and still underperform financially. Equipment utilization and test volume alone do not determine whether the laboratory supports a healthy bottom line. The reimbursement infrastructure surrounding those tests matters just as much.
This is also why laboratory financial projections deserve scrutiny. The relevant question is not only what the lab could bill under a modeled level of testing. Leadership needs to understand whether the practice has the payer environment, ordering behavior, reimbursement infrastructure, and ongoing management required to make that model viable.
A different physician-owned lab model exists
The traditional choices can make the decision appear fairly narrow.
A practice can continue sending molecular testing to a reference laboratory. Or it can bring appropriate testing in house and assemble the people and companies required to build and operate its own laboratory.
A third option is a physician practice can own the molecular laboratory while a specialized lab partner builds and manages the operating infrastructure around it long-term.
Under that model, the laboratory does not become another collection of providers for the practice to coordinate after launch. Laboratory development, equipment, staffing, testing operations, technology, compliance, reporting, reimbursement, and day-to-day oversight are managed as one connected operation, with accountability extending beyond the build itself.
For qualified physician groups, this is the model behind Phytest’s Molecular Lab Management.
Phytest builds, staffs, and manages physician-owned moderate-complexity molecular laboratories and their reimbursement infrastructure. The relationship continues after the laboratory opens because ongoing management is part of the service, not an operating responsibility handed back to the practice once implementation is complete.
The difference is accountability. Instead of practice leadership becoming the permanent connection between laboratory specialists, Phytest becomes an extension of the practice itself and is held accountable for the managed operating infrastructure.
The practice owns the lab and the existing ordering behavior
The physician practice owns the laboratory. It provides the physical space and is responsible for the associated facility expense. The practice also owns the laboratory equipment that Phytest helps source.
The practice’s physicians, staff, and leadership remain responsible for the internal behaviors that allow the lab to perform.
In practical terms:
- physicians need to direct appropriate testing to the practice’s molecular lab when that testing belongs there rather than defaulting to a reference laboratory;
- staff need to place orders correctly in the EHR;
- leadership needs to reinforce those behaviors across the practice.
Those responsibilities are different from hiring laboratory specialists, running reimbursement operations, managing the technical infrastructure, or coordinating the laboratory’s daily operating functions.
The distinction matters because a managed model should remove the need for practice leadership to become laboratory operators without removing the autonomy of ordering behaviors.
Phytest manages the specialized infrastructure. The practice creates the internal participation required for that infrastructure to work.
Determining if a practice is ready for an in-house molecular lab
A physician-owned molecular lab is not appropriate simply because a practice orders molecular testing.
The opportunity depends on several conditions working together such as the practice specialty, existing testing volume, the payer environment, available physical space for a lab, and operational readiness across the organization.
A practice may have meaningful testing volume but a payer environment that changes the economics. Another may have the right specialty and clinical interest but insufficient space or organizational readiness. A projected test volume also means little if physician ordering behavior does not support moving appropriate testing into the practice’s laboratory.
The purpose of evaluating these factors together is to determine whether an in-house molecular lab can function as a sustainable clinical and business operation for that particular practice.
That assessment should happen before equipment selection or projected laboratory revenue becomes the center of the decision.
Physician ownership does not require physician-practice lab management
The important choice is broader than whether to outsource molecular testing or build a laboratory.
For the right physician practice, molecular testing that is already part of patient care can support a physician-owned laboratory with its own clinical, operational, and financial value. What makes that opportunity practical is having the infrastructure to operate the laboratory after the build is complete.
Practice ownership and practice management of that infrastructure do not have to be the same thing.
Phytest’s fully managed model allows the practice to own the laboratory while a specialized partner remains responsible for building, staffing, managing, and supporting the operating infrastructure behind it. The practice participates where its physicians, staff, and leadership matter most without taking on the specialized laboratory-management functions itself.
That is the operating choice physician owners and COOs should understand before deciding whether an in-house molecular lab belongs in the practice.
For practices where the specialty, testing volume, payer environment, space, and readiness support that model, the next step is to evaluate the opportunity as a complete laboratory operation rather than a buildout project.




